PRT2527
Hematologic malignancies (CLL, NHL) and solid tumors
Key Facts
Indication
Hematologic malignancies (CLL, NHL) and solid tumors
Phase
Phase 1
Status
Active
Company
About Prelude Therapeutics
Prelude Therapeutics is dedicated to discovering and developing next-generation cancer treatments by targeting validated biological pathways with novel mechanisms. The company leverages its integrated discovery and development platform to advance a pipeline of small molecule candidates designed to address significant unmet needs in oncology. Its most advanced programs target SMARCA2/BRM and CDK9, with multiple candidates in clinical development. As a public company, Prelude is focused on generating clinical proof-of-concept data to validate its approach and create value for patients and shareholders.
View full company profile